Patent Application
20170181930
The present invention relates to a dental implant or an element thereof comprising a transmucosal portion, wherein at least a part of said trans-mucosal portion comprises a biocide. Moreover, the present invention relates to methods for preventing bio film formation on a transmucosal portion of a dental implant and for preventing or treating dental implant associated inflammation, comprising providing and implanting a dental implant or an element thereof according to the present invention. The present invention further relates to the use of a biocide for manufacturing a dental implant or element thereof, and to a biocide released from a dental implant or an element thereof according to the present invention for use in preventing and/or treating dental implant associated inflammation. Further the present invention relates to the use of a biocide for manufacturing denture teeth and/or denture resin.
Dental implants are an important option in oral rehabilitation. Typically, dental implants comprise a bone-integral part, also known as enossal or osseous part, anchoring the implant in the jawbone of the patient and a trans-mucosal portion spanning the gingiva/mucosa. Said parts of the implant may be combined in one single implant (one-piece or tissue-level implant), or may be embodied in two or more parts; in the case of two- or more piece implants (bone-level implant), typically the osseous part is separate from other elements, whereas the trans-mucosal portion and the crown may be separate parts or may be combined. In any case, the replacement of the visible part of the tooth, the crown, will be fixed onto the trans-mucosal portion. It is an advantage of two- or more-piece implants that the trans-mucosal portion may be changed while leaving the enossal portion in place. Thus, in two- or more-piece embodiments, the transmucosal element may be embodied as a mucosal former or as a healing cap, also termed “healing abutment”, when used during healing, or as an abutment, also known as “secondary element” for anchoring the crown in fixed restorations, or as “retention element” for fixing the prosthesis in removable restorations.
A common problem of dental implants is the formation of a, mostly bacterial, biofilm between the implant and the mucosa. This biofilm is not accessible to mechanical removal with a toothbrush, and frequently is the cause of inflammatory processes leading to peri-implant mucositis, which generally is reversible after appropriate treatment, or to peri-implantitis (Berglundh et al, (2011), J Clin Periodontol 38 Suppl 11: 188). Peri-implant mucositis has been estimated to occur in 80% of patients carrying dental implants, and at 50% of dental implants installed. What is more, peri-implantitis is diagnosed in 28 to 50% of dental implant patients and at 12 to 43% of dental implants installed (Zitzmann and Berglund (2008), J Clin Periodontol 35: 286). Untreated peri-implantitis can lead to bone defects and to loss of the implant.
For this reason, several methods of controlling biofilm formation on dental implants have been proposed, with an emphasis on mechanical removal of biofilms. Other attempts aimed at destroying biofilms by electric currents (Sahrmann et al. (2012), Clin Implant Dent Relat Res, doi: 10.1111/cid.12018, epub ahead of print). Recently, it was proposed to introduce grooves into the trans-mucosal portion of dental implants in order to improve contact between the mucosa and the trans-mucosal implant portion, in an attempt to exclude bio films from said area (Nevins et al. (2012), Int J Periodontics Restorative Dent 32: e131). In a similar train of thought, it was attempted to cover the trans-mucosal portion of an implant with adhesion molecules, e.g. laminin; however, it was found that such adhesion molecules are degraded over time, making such treatment ineffective (Lange et al. (2004), Dent Mater 20: 814-822). Further, implant abutments coated with soda-lime glass containing silver nanoparticles were experimentally used in a peri-implantitis model, but showed increased surface roughness and cracking of the coating (Lopez-Piriz et al. 2012, PLOS One 7(12), e86926, Martinez et al. 2014, PLOS One 9(1), e52861). Moreover, usability of such coatings in treatment of humans appeared questionable due to the black color of the coatings.
There is, thus, a need in the art for improved means and methods for preventing bio film formation on dental implants, in particular on the trans-mucosal portion thereof. Such improved means and methods are provided by the embodiments of the present invention.
Accordingly, the present invention relates to a dental implant or an element thereof comprising a trans-mucosal portion, wherein at least a part of said trans-mucosal portion comprises a biocide. The trans-mucosal portion can also be an integral part of the implant crown restoration.
As used in the following, the terms “have”, “comprise” or “include” or any arbitrary grammatical variations thereof are used in a non-exclusive way. Thus, these terms may both refer to a situation in which, besides the feature introduced by these terms, no further features are present in the entity described in this context and to a situation in which one or more further features are present. As an example, the expressions “A has B”, “A comprises B” and “A includes B” may both refer to a situation in which, besides B, no other element is present in A (i.e. a situation in which A solely and exclusively consists of B) and to a situation in which, besides B, one or more further elements are present in entity A, such as element C, elements C and D or even further elements.
Further, as used in the following, the terms “preferably”, “more preferably”, “most preferably”, “particularly”, “more particularly”, “specifically”, “more specifically” or similar terms are used in conjunction with optional features, without restricting alternative possibilities. Thus, features introduced by these terms are optional features and are not intended to restrict the scope of the claims in any way. The invention may, as the skilled person will recognize, be performed by using alternative features. Similarly, features introduced by “in an embodiment of the invention” or similar expressions are intended to be optional features, without any restriction regarding alternative embodiments of the invention, without any restrictions regarding the scope of the invention, and without any restriction regarding the possibility of combining the features introduced in such way with other optional or non-optional features of the invention.
The term “dental implant” is understood by the skilled person and relates to an element anchoring the restoration (crown of an artificial tooth or prosthesis) in a jawbone of a subject. As detailed herein above, dental implants may be manufactured as one-piece embodiments, as two-piece embodiments, or as three or more-piece embodiments. A one-piece dental implant, preferably, comprises at least (i) an enossal portion, anchoring the dental implant in the bone and (ii) a trans-mucosal portion spanning the gum/mucosa. It will be understood by the skilled person that the final dental implant, preferably, further comprises (iii) a crown, replacing the visible part of the tooth in the oral cavity. In two- or more-piece embodiments, preferably, at least one of the aforesaid elements is embodied as a discrete element. More preferably, in two- or more-piece embodiments, the enossal portion is embodied as a discrete element, the enossal element. Most preferably, in two- or more-piece embodiments, at least the enossal portion and the trans-mucosal portion are embodied as discrete elements. Preferably, in such a case, the enossal portion is a discrete element comprising a female screw thread, into which at least a trans-mucosal element can be anchored, preferably via a screw connection. Preferably, in two- or more-piece embodiments, the trans-mucosal element is a mucosal former, a healing cap (healing abutment), an abutment (secondary element) for fixed restorations, or a retention element for removable restorations. The abutment, preferably, can also be integrated into the final crown restoration, so that the crown is directly connected to the osseous implant part. Accordingly, the term “dental implant or element thereof comprising a trans-mucosal portion”, preferably, relates to a one-piece dental implant comprising a trans-mucosal portion; or the term relates to an element of a two- or more-piece dental implant comprising a trans-mucosal portion, i.e., preferably, a mucosal former, a healing cap, an abutment, a retention element or a crown as specified herein above. In a preferred embodiment, the dental implant is a long-term implant, i.e. preferably, a permanent implant; preferably, said long-term implant is implanted for at least one year, more preferably for at least five years, still more preferably for at least ten years, most preferably, for at least 20 years.
The term “trans-mucosal portion”, as used herein, relates to a portion of a dental implant or part thereof at least partially spanning the mucosa covering the jawbone, i.e. spanning the gum/mucosa. Accordingly, preferably, the trans-mucosal portion of a dental implant or element thereof is a portion spanning the section between the jawbone and the oral cavity. It is understood by the skilled person that, preferably, the trans-mucosal portion extends up to 2 mm, more preferably 1 mm into the oral cavity. Most preferably, however, the trans-mucosal portion is even with the mucosa or ends just below the mucosal margin, i.e. does not extend into the oral cavity.
The term “microorganism”, as used herein, is understood by the skilled person and relates to any unicellular, multicellular, or viral organism, which is invisible to the naked eye. Preferably, the microorganism is a eukaryotic or prokaryotic organism. More preferably, the microorganism is a bacterium or a yeast, most preferably of a species which is part of the oral flora. Preferably, the bacterium according to the present invention is a member of one of the genera Streptococcus, Fusobacterium, and Actinomyces. More preferably, the bacterium is Streptococcus viridens, S. mitis, S. oralis, S. mutans, or S. sobrinus. Most preferably, the bacterium is Porphyromonas gingivalis or P. intermedia. Preferably, the yeast according to the present invention is a member of the genus Candida, more preferably the yeast is C. albicans.
As used herein, the term “biocide” relates to any compound killing or inhibiting proliferation of at least one microorganism species and/or mediating immunosuppression. Preferably, the biocide is an antibacterial, antifungal, and/or antiviral compound. Preferably, the biocide is compatible with use in the oral cavity. The term “compatible with use in the oral cavity”, preferably, relates to the property of a biocide of not inducing severe adverse effects when administered in an effective concentration in the oral cavity. More preferably, compatible with use in the oral cavity relates to the property of a biocide of not inducing moderate adverse effects when administered in an effective concentration in the oral cavity. Most preferably, compatible with use in the oral cavity relates to the property of a biocide of not inducing adverse effects when administered in an effective concentration in the oral cavity. Preferred biocides of the present invention are compounds having antibacterial and/or immunosuppressive properties. As will be understood by the skilled person, the biocide, preferably, is released from the trans-mucosal portion of the dental implant or an element thereof according to the present invention, i.e., preferably, the biocide diffuses from said trans-mucosal portion of the dental implant or an element thereof into the vicinity, preferably into the layer between the mucosa and the trans-mucosal portion of the dental implant or an element thereof.
Preferably, the biocide is a preservative. A preferred preservative according to the present invention is benzoic acid or a derivative thereof, an antioxidant, sorbic acid or a derivative thereof, a propionate salt, a nitrite salt, a sulfite salt, or ethylenediaminetetraacetic acid (EDTA).
Preferably, the biocide is an antimycotic or an antiseptic compound, e.g. chlorhexidine. Preferred antimycotics of the present invention are clotrimazole, nystatin, fluconazole, and ketoconazole.
Also preferably, the biocide comprises or is an antibacterial compound. Antibacterial compounds, preferably, are bactericidal compounds, bacteriostatic compounds, or compounds inhibiting bacterial adhesion to a dental implant, more preferably of bacterial adhesion to the trans-mucosal portion. Preferred bactericidal compounds are antibiotics, including, preferably, at least one of the antibiotics amoxicillin, amoxicillin in combination with clavulanic acid, metronidazole, clindamycin, azithromycin, ciprofloxacin, tetracyclines (e.g. doxycycline, minocycline), or any arbitrary combination thereof (van Winkelhoff, A. J. (2012) European journal of oral implantology Suppl 5; S43-50). Preferred bacteriostatic compounds are bacteriostatic antibiotics including, e.g. preferably, sulfonamides, macrolides, and chloramphenicols. Preferred compounds inhibiting bacterial adhesion are surfactants.
Preferably, the biocide comprises or consists of at least one metal showing an oligodynamic effect, preferably, silver (Ag), gold (Au), mercury (Hg), copper (Cu), iron (Fe), lead (Pb), zinc (Zn), bismuth (Bi), platinum (Pt), cerium (Ce), and aluminum (Al). Preferably, the biocide comprises at least one of the aforesaid at least one metal in the form of an organic complex, e.g., preferably, as allantoinate, alginate, or as a complex with carboxymethylcellulose. More preferably, the biocide comprises at least one of the aforesaid at least one metal as ions, e.g. in the form of an oxide, a phosphate, carbonate, chloride, or sulfate, or in the form of a mixed salt, e.g. Ag/Ca/Na-Phosphate and the like. The skilled person knows how to select organic complexes or salts with appropriate properties, e.g., preferably, appropriate solubility and compatibility with the material of the dental implant. Still more preferably, the biocide comprises at least one of the aforesaid at least one metal in the metallic form, preferably as a solid or finely dispersed, e.g. as nanoparticles. Most preferably, the biocide comprises an alloy comprising at least one of the aforesaid metals. More preferably, the biocide is an alloy comprising at least one of Ag, Au, and Hg. Most preferably, the biocide is an amalgam comprising Hg and Ag or/and Au. In a preferred embodiment, the biocide is not silver nanoparticles comprised in a soda lime glass.
Immunosuppressive compounds are known to the skilled person. Preferably, the immunosuppressive compound is a glucocorticoid, an alkylating agent, an antimetabolite, an immunophilin interacting agent, or a mycophenolate. Preferably, the glucocorticoid is cortisol or dexamethasone. Preferably, the alkylating agent is a nitrogen mustard, e.g. cyclophosphamide, or a platinum compound. The antimetabolite, preferably, is selected from the list consisting of folic acid inhibitors or nucleotide analogues. Preferred immunophilin interacting agents are cyclosporine, tacromlimus, and pimecrolimus.
The biocide, preferably, is not a compound mediating adhesion of mucosal cells, such as laminin, fibronectin or nanoporous TiO2, and is not a growth factor acting on cells of the mucosa. More preferably, the biocide is not a polypeptide; most preferably, the biocide is not a biological macromolecule. In a preferred embodiment, the biocide does not comprise hyaluronic acid. In a further preferred embodiment, the biocide does not comprise a hyaluronic acid linked to a glycopeptide antibiotic, in particular vancomycin.
Preferably, the release of the biocide from the dental implant or element thereof is essentially constant over time, “essentially constant” relating to a decrease or increase of release of the biocide from the dental implant or element thereof, preferably of not more than 50%, more preferably of not more than 30%, most preferably of not more than 20% over a given time period. It will be understood by the skilled person that the dental implant or element thereof may be used for long-term decrease of biofilm formation on a dental implant. In such an application, the release of biocide from the dental implant or element thereof, preferably is essentially constant over at least six months, more preferably over at least two years, most preferably over at least five years. Further, the dental implant or element thereof may be used for sanitization of an existing implant site. In such an application, the release of biocide from the dental implant or element thereof, preferably is essentially constant over at least one week, more preferably over at least two weeks, most preferably over at least five weeks. It is understood by the skilled person that the term release, preferably, relates to a release of the biocide at such a rate that an effective concentration is obtained, preferably obtained in the cleft between the trans-mucosal portion and the mucosa. In a preferred embodiment, the release of biocide from the dental implant or element thereof is used for prevention or treatment of inflammation.
Preferably, the biocide is comprised in an appropriate carrier. A preferred carrier comprises the biocide of the present invention and is adapted to release said biocide at a constant, preferably slow, rate. Preferred carriers are gels or plastics, more preferably with a pore size appropriate for adequate release of the biocide. Appropriate carriers with the aforesaid properties are known to the skilled person.
Preferably, the biocide is comprised as an integral constituent within said trans-mucosal portion. Thus, the biocide, preferably is included in the material of the dental implant or element thereof in a manner allowing diffusion of the biocide into the surrounding medium. E.g., in case the biocide is an alloy or an amalgam, said alloy or amalgam may be the material the trans-mucosal portion consists of. Alternatively, the biocide, preferably the alloy or amalgam, may be permanently fixed to the dental implant or element thereof as a coating, as a ring or as one or more pins, e.g. by compression molding or by an other method known to the skilled person. In a preferred embodiment, the biocide is permanently fixed to the dental implant or element thereof as a ring fitting in a groove of said dental implant or element thereof. Also preferably, the biocide is comprised in a removable means, preferably a ring, mountable onto the trans-mucosal portion of the dental implant or element thereof. It is however also envisaged that the biocide is comprised in a screw fitting into one or more female screw thread(s) present in the trans-mucosal portion. As will be appreciated by the skilled person, the use of removable means is particularly advantageous in sanitization of existing implant sites, since the kind of biocide comprised in the removable means may be adjusted according to needs. E.g., preferably, in a first step, a bacterial infection may be resolved by administering an antimicrobial compound as specified elsewhere herein, and in a second step, inflammation may be healed by administering an immunosuppressant. In a third step, preferably, recurrent infection may be prevented by providing an implant releasing a biocide according to the present invention. Also preferably, the biocide is comprised in a cavity of said dental implant or element thereof, and, more preferably, said cavity is connected to the environment via at least one aperture comprised in said transmucosal portion. More preferably, the biocide is comprised in said cavity as a slowly-dissolving solid or within a carrier, as specified herein above. Thus, in a preferred embodiment, the biocide is comprised in a container abutment. In a further preferred embodiment, said biocide is comprised in a removable container abutment, which can be specifically used as a dispenser for a biocide or a pH-regulator, preferably in a sanitizing phase.
In a preferred embodiment, at least a part of said trans-mucosal portion comprises a pH-regulator. Preferably, a pH-regulator is a buffer compound or an alkaline compound, increasing the pH of the peri-implant surface or pouch and/or buffering low pH of the peri-implant surface or pouch. In a further preferred embodiment, the pH-regulator is comprised in a container abutment of the present invention. Suitable buffer compounds and alkaline compounds are known to the skilled person.
Advantageously, the dental implant or element thereof of the present invention applies the transmucosal portion of said device as a dispenser, inhibiting biofilm formation on said trans-mucosal portion. Since dental implant associated inflammation events are associated with growth of microorganisms in said portion of the dental implant, such inflammation can be ameliorated or prevented.
The definitions made above apply mutatis mutandis to the following. Additional definitions and explanations made further below also apply for all embodiments described in this specification mutatis mutandis.
The present invention further relates to a dental prosthesis comprising at least one denture tooth and a base, wherein said base or a part thereof and/or at least one artificial tooth or a part thereof comprise(s) a biocide.
Moreover, the present invention relates to a use of a biocide for manufacturing denture teeth and/or denture resin.
The term “dental prosthesis”, as used herein, relates to a device substituting at least one defective or missing tooth in a subject. Preferably, the dental prosthesis is removable, i.e., preferably is not implanted, more preferably, the dental prosthesis is a complete denture or a partial denture. Preferably, the dental prosthesis comprises at least one artificial tooth, preferably consisting of synthetic material, more preferably acrylic resin, most preferably polymethylmethacrylate. Preferably, the dental prosthesis further comprises a base, preferably consisting of the same material as the at least one synthetic tooth. Thus, removable tooth restorations, preferably, comprise at least one denture tooth and a denture base made of denture resin. These restorations are termed “overdentures” when retained at implant abutments/retainers, or “complete dentures” when solely supported by the mucosa.
Preferably, the dental prosthesis comprises a biocide as specified elsewhere herein. Preferably, only the base of the dental prosthesis comprises a biocide. Thus, preferably, the biocide is released from the material constituting the dental prosthesis according to the present invention.
The present invention also relates to a method for preventing bio film formation on a transmucosal portion of a dental implant after implantation, comprising providing a dental implant or an element thereof according to any one of claims 1 to 15, and thereby preventing bio film formation on a dental implant after implantation.
The present invention also relates to a method for preventing bio film formation on a dental prosthesis comprising at least one dental tooth and a denture base or an element thereof, said method comprising providing a dental prosthesis comprising a biocide, and, thereby, preventing biofilm formation on a dental prosthesis.
The method for preventing bio film formation of the present invention, preferably, is an in vivo method. Moreover, it may comprise steps in addition to those explicitly mentioned above.
Preferably, said method is performed on a healthy individual. More preferably, said method is a cosmetic method administered to avoid the enossal/osseous implant portion to become visible in the oral cavity. Exposure of the implant surface would be encountered with color deviation and cosmetic impairment.
The term “preventing biofilm formation” refers to impeding or precluding biofilm formation for a certain period of time. It will be understood that said period of time is dependent on the amount of the biocide which is released, and on individual factors of the subject carrying the dental implant or element thereof. It is to be understood that prevention may not be effective in all subjects carrying the dental implant or element thereof according to the present invention.
However, the term requires that a statistically significant portion of subjects of a cohort or population are effectively prevented from bio film formation. Preferably, a cohort or population of subjects is envisaged in this context, which normally, i.e. without preventive measures according to the present invention, would develop a bio film as referred to herein. Whether a portion is statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools discussed elsewhere in this specification.
The term “bio film” is known to the skilled person and relates to a group of microorganisms in which cells adhere to each other on a surface. Preferably, bacterial cells are the cells mediating adherence to a dental implant in the bio film according to the present invention. Also preferably, the biofilm is a biofilm located between a dental implant and the surrounding mucosa and/or around the mucosal margin.
Also preferably, the bio film is a bio film located at the denture teeth and/or, more preferably, between the denture base and the mucosa. Disorders associated with bio film formation between the denture base and the mucosa are, e.g., preferably, denture stomatitis, chronic atrophic candidiasis, Candida-associated denture induced stomatitis, and denture-associated erythematous stomatitis.
The present invention further relates to a method for preventing or treating dental implant associated inflammation, comprising providing a dental implant or an element thereof according to the present invention, implanting said dental implant or an element thereof at a site afflicted or suspected to become afflicted with dental implant associated inflammation, thereby preventing or treating dental implant associated inflammation.
The method for preventing or treating dental implant associated inflammation of the present invention, preferably, is an in vivo method. Moreover, it may comprise steps in addition to those explicitly mentioned above.
The term “preventing”, as used in the context of the method for preventing or treating dental implant associated inflammation refers to retaining health with respect to the diseases or disorders referred to herein for a certain period of time in a subject. It is to be understood that prevention may not be effective in all subjects treated with the compound according to the present invention. However, the term requires that a statistically significant portion of subjects of a cohort or population are effectively prevented from suffering from a disease or disorder referred to herein or its accompanying symptoms. Preferably, a cohort or population of subjects is envisaged in this context which normally, i.e. without preventive measures according to the present invention, would develop a disease or disorder as referred to herein. Whether a portion is statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools discussed elsewhere in this specification.
The term “treating” refers to ameliorating the diseases or disorders referred to herein or the symptoms accompanied therewith to a significant extent. Said treating as used herein also includes an entire restoration of the health with respect to the diseases or disorders referred to herein, preferably resolution of dental implant associated inflammation. It is to be understood that treating as used in accordance with the present invention may not be effective in all subjects to be treated. However, the term shall require that a statistically significant portion of subjects suffering from a disease or disorder referred to herein can be successfully treated. Whether a portion is statistically significant can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools, e.g., determination of confidence intervals, p-value determination, Student's t-test, Mann-Whitney test etc. Preferred confidence intervals are at least 90%, at least 95%, at least 97%, at least 98% or at least 99%. The p-values are, preferably, 0.1, 0.05, 0.01, 0.005, or 0.0001. Preferably, the treatment shall be effective for at least 60%, at least 70%, at least 80%, or at least 90% of the subjects of a given cohort or population.
As used herein, the term “dental implant associated inflammation” relates to inflammatory processes occurring at the site in an oral cavity where a dental implant was implanted. Preferably, said inflammation is located in a region of the peri-implant mucosa contacting a dental implant. More preferably, dental implant associated inflammation is dental peri-implant mucositis and/or dental peri-implantitis.
Moreover, the present invention also relates to a biocide released from a dental implant or from an element thereof according to the present invention for use in preventing and/or treating dental implant associated inflammation.
In a preferred embodiment, at least two biocides are administered for preventing and/or, preferably, treating dental implant associated inflammation. In a preferred embodiment, said least two biocides are administered simultaneously. In a more preferred embodiment, said least two biocides are administered one after the other, i.e., successively.
Further, the present invention relates to a method for producing a dental implant or an element thereof, comprising including a biocide in at least a part of a trans-mucosal portion of said dental implant or element thereof.
Moreover, the present invention relates to a use of a biocide for manufacturing a dental implant or element thereof, wherein, preferably, the dental implant is a dental implant or element thereof according to the present invention.
All references cited in this specification are herewith incorporated by reference with respect to their entire disclosure content and the disclosure content specifically mentioned in this specification.
In view of the above, the following embodiments are preferred:
A dental implant or an element thereof comprising a trans-mucosal portion, wherein at least a part of said trans-mucosal portion comprises a biocide.
The dental implant or element thereof of embodiment 1, wherein said biocide is an antimicrobial and/or immunosuppressive compound.
The dental implant or element thereof of embodiment 1 or 2, wherein said biocide is compatible with use in the oral cavity.
The dental implant or element thereof of any one of embodiments 1 to 3, wherein said antimicrobial compound is a bactericidal compound, a bacteriostatic compound, or a compound inhibiting bacterial adhesion to a dental implant.
The dental implant or element thereof of any one of embodiments 1 to 4, wherein said bactericidal compound is a metal, preferably at least one of Ag, Hg and Au, or an antibiotic, preferably amoxicillin, amoxicillin in combination with clavulanic acid, metronidazole, clindamycin, azithromycin, ciprofloxacin, a tetracycline, or any arbitrary combination thereof.
The dental implant or element thereof of any one of embodiments 1 to 4, wherein the bacteriostatic compound is a preservative, preferably benzoic acid or a derivative thereof, an antioxidant, sorbic acid or a derivative thereof, a propionate salt, a nitrite salt, a sulfite salt, or ethylenediaminetetraacetic acid (EDTA).
The dental implant or element thereof of any one of embodiments 1 to 4, wherein the immunosuppressive compound is a glucocorticoid, an alkylating agent, an antimetabolite, an immunophilin interacting agent, or a mycophenolate.
The dental implant or element thereof of any one of embodiments 1 to 7, wherein, after implantation, said biocide is released from said trans-mucosal portion.
The dental implant or element thereof of any one of embodiments 1 to 8, wherein, after implantation, said biocide is released from said part of said trans-mucosal portion at an essentially constant rate for at least one week, preferably for at least four weeks, more preferably at least six months, most preferably for at least two years.
The dental implant or element thereof of any one of embodiments 1 to 9, wherein said biocide is comprised as an integral constituent within said trans-mucosal portion.
The dental implant or element thereof of any one of embodiments 1 to 9, wherein said biocide is comprised in a removable means, preferably a ring, mountable onto said trans-mucosal portion.
The dental implant or element thereof of any one of embodiments 1 to 9, wherein said biocide is comprised in a cavity of said dental implant or element thereof, and wherein said cavity is connected to the environment via at least one aperture comprised in said trans-mucosal portion.
The dental implant or element thereof of any one of embodiments 1 to 12, wherein said biocide is not a compound mediating adhesion of mucosal cells.
The dental implant or element thereof of any one of embodiments 1 to 13, wherein said biocide is not a polypeptide.
The dental implant or element thereof of any one of embodiments 1 to 14, wherein said biocide is not a biological macromolecule.
A method for preventing biofilm formation on a trans-mucosal portion of a dental implant after implantation, comprising providing a dental implant or an element thereof according to any one of embodiments 1 to 15, and thereby preventing biofilm formation on a dental implant after implantation.
A method for preventing or treating dental implant associated inflammation, comprising providing a dental implant or an element thereof according to any one of embodiments 1 to 15, implanting said dental implant or an element thereof at a site afflicted or suspected to become afflicted with dental implant associated inflammation, thereby preventing or treating dental implant associated inflammation.
A biocide released from a dental implant according to any one of embodiments 1 to 15 for use in preventing and/or treating dental implant associated inflammation
The method according to embodiment 16 or 17, or the biocide released from a dental implant according to embodiment 18, wherein dental implant associated inflammation is dental peri-implant mucositis and/or dental peri-implantitis.
A method for producing a dental implant or an element thereof, comprising including a biocide in at least an element of a trans-mucosal portion of said dental implant or element thereof.
Use of a biocide for manufacturing a dental implant or element thereof.
The use of embodiment 22, wherein said dental implant or element thereof is a dental implant or element thereof according to any one of embodiments 1 to 15.
A dental prosthesis comprising at least one denture tooth and a base, wherein said base or a part thereof and/or at least one artificial tooth or a part thereof comprise(s) a biocide.
The dental prosthesis of embodiment 23, wherein said biocide comprises silver nanoparticles.
In preferred embodiments, the present invention relates to the following:
A dental implant (118) or an element thereof comprising a trans-mucosal portion (122), wherein at least a part of said trans-mucosal portion (122) comprises a biocide (132) and/or a pH regulator.
The dental implant (118) or element thereof of embodiment 25, wherein said biocide (132)
(i) is comprised as an integral constituent within said trans-mucosal portion (122);
(ii) is permanently fixed to the dental implant (118) or element thereof as a ring (142), as one or more pins (144), or is comprised in a cavity (134) of said dental implant (118) or element thereof, wherein said cavity (134) is connected to the environment via at least one aperture (136) comprised in said trans-mucosal portion (122); or
(iii) is comprised in a removable means mountable onto said trans-mucosal portion (122).
The dental implant (118) or element thereof of embodiment 25 or 26, wherein said biocide (132) is comprised in a removable means, wherein said removable means is a ring (142) or one or more pins (144) mountable onto said trans-mucosal portion (122).
The dental implant (118) or element thereof of embodiment 25, wherein said pH-regulator is comprised in a cavity (134) of said dental implant (118) or element thereof and wherein said cavity (134) is connected to the environment via at least one aperture (136) comprised in said trans-mucosal portion (122).
The dental implant (118) or element thereof of any one of embodiments 25 to 28, wherein said biocide (132) is an anti-inflammarory compound, preferably an antibacterial, antimycotic, antiviral, antiseptic, and/or immunosuppressive compound.
The dental implant (118) or element thereof of embodiment 29, wherein said antibacterial compound is a bactericidal compound, a bacteriostatic compound, or a compound inhibiting bacterial adhesion to a dental implant.
The dental implant (118) or element thereof of embodiment 30, wherein said bactericidal compound is a metal, preferably at least one of silver (Ag), mercury (Hg) and gold (Au), or an antibiotic, preferably amoxicillin, amoxicillin in combination with clavulanic acid, metronidazole, clindamycin, azithromycin, ciprofloxacin, a tetracycline, or any arbitrary combination thereof.
The dental implant (118) or element thereof of embodiment 29, wherein said immunosuppressive compound is a glucocorticoid, an alkylating agent, an antimetabolite, an immunophilin interacting agent, or a mycophenolate.
A biocide (132) and/or a pH regulator for use in preventing and/or treating dental implant associated inflammation, wherein said biocide (132) and/or pH regulator are/is released from a dental implant (118) according to any one of embodiments 25 to 32.
The biocide (132) and/or pH regulator for use according to embodiment 33, wherein said dental implant associated inflammation is dental peri-implant mucositis and/or dental peri-implantitis.
The biocide (132) and/or pH regulator for use according to embodiment 33 or 34, wherein said use is treating dental implant associated inflammation and wherein said treating comprises administering at least two different biocides, preferably successively administering at least two different biocides.
The biocide (132) and/or pH regulator for use according to any one of embodiments 33 to 35, wherein said use is treating dental implant associated inflammation and wherein said treating comprises administering an antimicrobial compound followed by administration of an immunosuppressant.
A method for producing a dental implant (118) or an element thereof, comprising including a biocide and/or pH regulator in at least an element of a transmucosal portion (122) of said dental implant (118) or element thereof.
Use of a biocide and/or pH regulator for manufacturing a dental implant (118) or element thereof.
The use of embodiment 38, wherein said dental implant (118) or element thereof is a dental implant (118) or element thereof according to any one of embodiments 25 to 32.
The following Examples shall merely illustrate the invention. They shall not be construed, whatsoever, to limit the scope of the invention.
In a preferred embodiment, a complete dental implant 118 with restoration (crown) 124 of the present invention is a device as schematically represented in
The following embodiments include descriptions of distal elements of two- or more-piece dental implants, which can, preferably, be removed while leaving the enossal element in place. Accordingly, these embodiments are suited for the same purpose as the one-piece embodiment described before. However, the following embodiments are also particularly suited for treating prevalent dental implant associated inflammation. In the following embodiments, preferably, the distal, trans-mucosal element 118, 120 may be a mucosal former, a healing cap (healing abutment), an abutment (secondary element) for fixed restorations, or a retention element for removable restorations. In preferred embodiments, the polymeric abutment according to
In a preferred embodiment, the dental implant 118 of the present invention is an element as schematically represented in
In a preferred embodiment, the distal, trans-mucosal element 118, 120 of the present invention is an element (abutment) as schematically represented in
In another preferred embodiment, the distal, trans-mucosal element 118, 120 of the present invention is an element as schematically represented in
In another preferred embodiment, the distal, trans-mucosal element 118, 120 of the present invention is an element as schematically represented in
In a further preferred embodiment, the distal, trans-mucosal element 118, 120 of the present invention is an element as schematically represented in
In another preferred embodiment, the element of a dental implant 118 of the present invention is a restoration (crown) 124 as schematically represented in
| Number | Date | Country | Kind |
|---|---|---|---|
| 14165087.9 | Apr 2014 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2015/058268 | 4/16/2015 | WO | 00 |
